Syndesi Therapeutics is a biopharmaceutical company focused on developing innovative molecules that uniquely modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the communication between neurons in the brain. This approach represents a promising method for treating dementia and other cognitive impairments. The company operates in the healthcare and pharmaceutical market, targeting patients with cognitive disorders. Syndesi's business model involves the research and development of these molecules, with the aim of bringing them to market through clinical trials and regulatory approval. Revenue is generated through partnerships, licensing agreements, and eventually, the sale of approved treatments. The lead molecule, SDI 118, has shown positive results in Phase I studies and is based on over 15 years of research on SV2A at UCB. Syndesi holds an exclusive license to its molecules and technology from UCB, a leader in SV2A research.

Keywords: biopharmaceutical, SV2A, synaptic transmission, dementia, cognitive impairment, SDI 118, clinical trials, licensing, UCB, innovation.